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Embryonic development of the mamma­
lian face relies on a sequence of complex and 
interdependent molecular, cellular, and tis­
sue interactions. Disruption of these develop­
mental processes often results in orofacial 
defects, which are the most common of all 
congenital disorders in humans. The second 
most frequent non  syndromic orofacial defect 
is isolated cleft palate, which has a frequency 
of approximately 1:2,500 in European new­
borns (Cobourne 2004). Its effect on speech, 
hearing, appearance, and cognition leads 
to long­lasting adverse outcomes impair­
ing social integration (Vallino et al. 2008). 
Isolated cleft palate is currently considered 
to have a multifactorial etiology in which a 
deleterious genetic background is combined 
with environmental factors. Gene linkage and 
association studies indicate that the patho­
genesis of non  syndromic isolated cleft palate 
relies on a combination of multiple mutations 
in different genes (Lidral et al. 2008), and 
epidemiological studies have revealed a cor­
relation between increased risk for oral cleft 
and exposure to dioxin­like chemicals during 
pregnancy (Leite et al. 2002; Murray 2002). 
In laboratory animals, notably in mice, expo­
sure to 2,3,7,8­tetrachloro  dibenzo­p­dioxin 
(TCDD) during organogenesis causes cleft 
palate (Courtney and Moore 1971; Couture 
et al. 1990). Because developing palatal shelves 
of human, rat, and mouse respond similarly to 
TCDD exposure in organ cultures (Abbott 
et al. 1999; Couture et al. 1990), the mouse is 
an ideal in vivo model for studying teratogenic 
effects of dioxins.
At the molecular level, TCDD alters gene 
expression by activating the aryl hydrocarbon 
receptor (AHR). Unliganded AHR resides 
in the cytoplasm in an inactive complex with 
heat­shock molecules. Binding of TCDD to 
AHR causes the dissociation of the receptor 
from the complex and its translocation into 
the nucleus, where it dimerizes with the AHR 
nuclear translocator (ARNT). The AHR/
ARNT heterodimer functions as a transcrip­
tional activator by binding to specific DNA 
sequences called dioxin response elements 
(DREs) located in the regulatory regions of 
AHR­responsive genes (Beischlag et al. 2008; 
Pohjanvirta et al. 2011). Mice with a homozy­
gous ablation of the Ahr gene suffer from vari­
ous age­related pathologies; this suggests that 
AHR exerts important physiological functions 
(Fernandez­Salguero et al. 1995). Thus, under­
standing the molecular mechanisms through 
which TCDD exposure results in a cleft palate 
may provide clues not only to the mechanisms 
of TCDD teratogenicity but also to the nature 
of homeostatic AHR functions.
There is increasing evidence that environ­
mental pollutants such as dioxin­like com­
pounds interfere with all­trans­retinoic acid 
(atRA) signaling (Novák et al. 2008). atRA is 
a pleiotropic, paracrine or autocrine signaling 
molecule produced from vitamin A through 
oxidative reactions carried out by the cyto­
solic retinaldehyde dehydro  genases RALDH1, 
RALDH2, and RALDH3 (Duester 2008). 
atRA acts as a hormone by binding to and 
activating α, β, and γ isotypes of atRA recep­
tors (RARs; RARA, RARB, RARG, respec­
tively), which belong to the nuclear hormone 
receptor superfamily and function as ligand­
dependent transcription factors inter  acting 
with regulatory regions located in target 
genes. In a large variety of tissues, RARs 
act by forming heterodimers with one of 
the rexinoid receptors, retinoid X receptor 
(RXR; α, β, or γ isotypes), which bind 9­cis 
but not atRA (Mark et al. 2006). Similarities 
between dioxin toxicity and atRA deficiency 
or excess have often been pointed out (Nilsson 
and Håkansson 2002; Novák et al. 2008). 
Accordingly, atRA excess induces a cleft palate 
(Abbott et al. 1989), as does TCDD expo­
sure (Courtney and Moore 1971; Couture 
et al. 1990). In many instances, the effects of 
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Ba c k g r o u n d: Palate development depends on complex events and is very sensitive to disruption. 
Accordingly, clefts are the most common congenital malformations worldwide, and a connection is 
proposed with fetal exposure to toxic factors or environmental contaminants, such as dioxins. There 
is increasing evidence that dioxin interferes with all-trans-retinoic acid (atRA), a hormone-like sig-
nal derived from vitamin A, which plays an essential role during embryonic development. Although 
similarities have been described between dioxin-induced toxicity and the outcome of altered atRA 
signaling during palate development, their relationship needs to be clarified.
oBjectives: We used a genetic approach to understand the interaction between atRA and dioxin 
and to identify the cell type targeted by dioxin toxicity during secondary palate formation in mice.
Me t h o d s : We analyzed the phenotype of mouse embryos harboring an atRA-sensitive reporter trans-
gene or bearing null mutations for atRA-synthesizing enzymes (RALDH) or atRA receptors (RAR) 
and maternally exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) at gestation day 10.5.
re s u l t s: We found that an intact atRA signal was required to enable TCDD to induce cleft palate. 
This mandatory atRA signal was generated through the activity of RALDH3 in the nasal epithelium 
and was transduced by RARγ (RARG) in the nasal mesenchyme, where it notably controlled aryl 
hydrocarbon receptor (Ahr) transcript levels. TCDD also did not alter the developmental pattern of 
atRA signaling during palate formation.
co n c l u s i o n s: TCDD-induced alteration of secondary palate development in the mouse appears 
to depend on atRA signaling, which controls AHR expression. This mechanism is likely conserved 
throughout vertebrate evolution and may therefore be relevant in humans.
key w o r d s : AHR, cleft, mesenchyme, mouse, nasal epithelium, RAR, retinaldehyde dehydrogenase 
(RALDH), teratogenesis, 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). Environ Health Perspect 
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TCDD on atRA­controlled processes in vitro 
appear to be mediated by AHR either interfer­
ing positively or negatively with atRA signal­
ing in certain cell types or changing activity 
of the enzymes responsible for transformation 
of retinoids (Novák et al. 2008). However, 
further investigation is needed to confirm that 
the mechanisms shown to operate in vitro are 
indeed mediating TCDD­induced defects 
in vivo.
In this study, we used mouse embryos har­
boring null mutations in the genes coding for 
RALDH3, RARA, or RARG to unravel the 
possible interaction between atRA and TCDD 
during palate development and to reassess the 
etiology of TCDD­induced cleft palate. We 
demonstrate that TCDD does not alter the 
pattern of atRA signaling in the embryonic 
face. However, we show that an atRA signal 
generated through the activity of RALDH3 
in the nasal epithelium and transduced by 
RARG in the nasal mesenchyme is mandatory 
to enable TCDD to induce cleft palate when 
administered at gestation day (GD) 10.5, 
notably through controlling the levels of Ahr 
expression. In addition, our results suggest 
that TCDD acts not directly on the develop­
ing palatal shelves, but on the mesenchyme 
adjacent to the nasal epithelium.
Materials and Methods
Animal use. Mice were housed in an animal 
facility licensed by the French Ministry of 
Agriculture (agreement B67­218­5). Animal 
experiments were supervised by one of the 
authors who is qualified for experimenting 
with mice, in compliance with the European 
legislation on care and use of laboratory ani­
mals (agreement 67­205). The mice were 
treated humanely and with regard for allevia­
tion of suffering.
Mice genotyping and treatments. The trans­
genic line Tg(RARE-Hspa1b/lacZ)12Jrt and 
the lines carrying the Ahrtm1Bra­, Raratm3.1Ipc­, 
Rargtm1Ipc­, and Aldh1a3tm1.1Pcn­null alleles were 
genotyped as previously described (Chapellier 
et al. 2002; Dupé et al. 2003; Lohnes et al. 
1993; Rossant et al. 1991; Schmidt et al. 
1996). Noon of the day a vaginal plug was 
observed was considered GD0.5. At GD10.5, 
pregnant mice were given a single dose of 100 
mg/kg atRA (Biomol International, Plymouth 
Meeting, PA, USA) or 30 μg/kg TCDD 
(Wellington Laboratories, Guelph, ON, 
Canada) dissolved in sunflower oil (Sigma, 
Lyon, France) by oral gavage. The number 
of fetuses and litters analyzed and an over­
view of cleft palate occurrence as a function 
of treatments and genotypes are presented in 
Supplemental Material, Table 1 (http://dx.doi.
org/10.1289/ehp.1003075).
Phenotype analysis. We stained skeletons 
with Alcian blue and Alizarin red as previously 
described (Lufkin et al. 1992). For detection 
of β­galactosidase activity, we performed 
5­bromo­4­chloro­3­indolyl­beta­d­galacto­
pyranoside (XGal)­based staining (Rossant 
et al. 1991) and embryos were post  fixed in 
Bouin’s fluid, embedded in paraffin, seri­
ally sectioned, and then counterstained with 
eosin. Whole­mount in situ RNA hybridiza­
tion was performed as previously described 
(Wendling et al. 2001). In situ hybridization 
and immuno  histochemistry on cryosections 
were also performed as previously described 
(Vernet et al. 2006), using embryos that were 
fixed for 1 hr in 4% (wt/vol) phosphate­
  buffered paraformaldehyde at 4°C.
RNA analysis. We prepared transverse slices 
of the nasopalatal region from GD11.5 embryos 
(n ≥ 3 for each condition) from which the eyes 
and the maxillary component of first bran­
chial arches were removed. Wild­type (WT) or 
RAR­deficient (Rara–/–/Rarb–/–/Rarg–/–) mouse 
embryonic fibroblasts (MEFs) were maintained 
as previously described (Epping et al. 2007). 
At subconfluency, we added cycloheximide 
(10–6 M) 1 hr before atRA (10–6 M) and har­
vested cells 6 hr after atRA. We extracted total 
RNA using Trizol reagent (Invitrogen, Life 
Technologies, Villebon­sur­Yvette, France), 
converted it to cDNA, and analyzed it by real­
time polymerase chain reaction performed in 
a Realplex Mastercycler (Eppendorf, Le Pecq, 
France). We normalized the transcript levels 
relative to that of Rplp0 (ribosomal protein, 
large, P0) transcript (MGI:1927636), whose 
expression is not altered in mutant mice or in 
atRA­ or TCDD­treated fetuses. We analyzed 
each sample in triplicate and assessed results 
using Student’s t­test.
Results
TCDD administration and excess atRA at 
GD10.5 induce identical cleft palates. To com­
pare the morphological outcomes of TCDD 
and atRA treatments on palatal develop  ment, 
we analyzed skeletons of 34 GD18.5 fetuses. 
An oral dose of TCDD (30 μg/kg) to pregnant 
WT mice at GD10.5 always (n = 27 fetuses) 
inhibited the development of the palatal pro­
cesses of the maxillary bones, which were 
hypoplastic, as well as those of the palatine 
bones, which were agenic (Figure 1B). In con­
trast, other parts of these bones (e.g., alveo  lar, 
orbital, and zygomatic processes) were normal 
[see Supplemental Material, Figure 1 (http://
dx.doi.org/10.1289/ehp.1003075)]. Treatment 
of pregnant WT mice with atRA (100 mg/kg) 
at GD10.5 also systematically induced a cleft 
palate (n = 7 fetuses), which was indistinguish­
able from its TCDD­induced counterpart 
(Figure 1C; see also Supplemental Material, 
Figure 1) and was not accompanied by other 
craniofacial defects. Therefore, both TCDD 
exposure and atRA excess at GD10.5 induce a 
cleft palate through inhibition of palatal shelf 
development. This finding raised the possibility 
either that atRA activates AHR or that TCDD 
mimics the effects of atRA excess through acti­
vating this pathway.
Excess atRA does not produce cleft palate 
through activating AHR, and reciprocally, 
TCDD does not modify the developmental 
pattern of atRA signaling in the face. To test 
for these hypotheses, we first intercrossed 
Ahr+/– mice and then fed the pregnant females 
atRA at GD10.5 and examined their prog­
eny at GD18.5. We observed a cleft palate 
in all Ahr–/– fetuses (n = 5), thus ruling out 
the possibility that atRA was activating AHR 
to induce a cleft palate [see Supplemental 
Material, Figure 2 (http://dx.doi.org/10.1289/
ehp.1003075)]. Then, to test whether TCDD 
activated atRA signaling, we analyzed its effects 
on embryos harboring the Tg(RARE-Hspa1b/
lacZ)12Jrt transgene (Rossant et al. 1991), 
which is used to monitor variations in atRA 
Figure 1. TCDD and atRA similarly impair palate development: ventral view of palatal regions of GD18.5 WT 
fetuses treated at GD10.5 with oil vehicle (A), TCDD (B), and atRA (C). Bone was stained with Alizarin red 
and cartilage with Alcian blue. Both TCDD and atRA induced cleft palates through which one can see the 
presphenoid and vomer bones. The arrows indicate the length of the palatal processes of maxillary bones. 
Abbreviations: i, incisive bone; if, incisive foramen; m, maxillary bone; p, palatine bone; ppi, palatal process 
of incisive bone; ppm, palatal process of maxillary bone; ppp, palatal process of palatine bone; ps, pres-
phenoid bone; v, vomer bone. Bar = 1 mm.
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signaling (Duester 2008). We analyzed its 
activity at GD10.75, GD11.5, and GD12.5 
(n = 5 embryos at each developmental age) 
and found that control and TCDD­treated 
fetuses displayed identical patterns of XGal 
staining in the frontonasal region (Figure 2), 
indicating that the developmental pattern 
of atRA signaling remained unaltered upon 
TCDD treatment. To extend these observa­
tions, we quantified the mRNA levels of lacZ 
and endogenous atRA­target genes, including 
Crabp2 (cellular retinoic acid binding protein), 
Rara, and Rarg (Balmer and Blomhoff 2002). 
In agreement with the lack of effect of TCDD 
on transgene activity, we did not detect a sig­
nificant difference for any of these four genes 
in the nasopalatal region of TCDD­treated 
(n = 3) or control (n = 3) embryos. In addi­
tion, we verified that Rxra mRNA level was 
not altered, ruling out the possibility that 
TCDD acted through modulating expression 
of the RAR partner (Figure 3). Importantly, 
we confirmed the efficiency of TCDD treat­
ment by the induction of Cyp1a1 (cytochrome 
P450 1A1), a well­established target gene of 
TCDD­activated AHR (Abbott et al. 1999). 
Together, these results demonstrate that the 
ability of TCDD to induce a cleft palate can­
not be accounted for by increased or ectopi­
cally activated atRA signaling.
TCDD is unable to induce a cleft pal-
ate when atRA signaling is impaired. The 
above results did not exclude the possibility 
that endogenous, atRA­dependent events are 
required to allow TCDD­induced inhibition 
of palatal shelf development. Between GD10.5 
and GD12.5, we detected atRA signals in the 
frontonasal region but not in the palate per se 
(Figure 4B). During this period of develop­
ment, RALDH3 is the sole RA­synthesizing 
enzyme expressed in the nasopalatal region as 
assessed by in situ hybridization (Figure 4A) 
and by the complete disappearance of 
Tg(RARE-Hspa1b/lacZ)12Jrt activity in 
Aldh1a3–/– fetuses (Figure 4C). RARA and 
RARG are the sole nuclear receptors driving 
atRA activity during craniofacial development 
(Lohnes et al. 1994). To test the possibility 
that TCDD relies on endogenous atRA to 
induce cleft palate, we impaired atRA signaling 
in vivo through ablation of genes coding for 
atRA receptors or atRA­synthesizing enzymes. 
Thus, mutant mice carrying Rara­, Rarg­, or 
Aldh1a3­null alleles were mated, and we dosed 
pregnant females at GD10.5 with TCDD or 
vehicle [see Supplemental Material, “Material 
and Methods” (http://dx.doi.org/10.1289/
ehp.1003075)]. We analyzed skulls from 
GD18.5 null mutants (i.e., Rara–/–, Rarg–/–, 
and Aldh1a3–/–) and control WT littermates 
(n ≥ 3 for each genotype and treatment). All 
Rara–/– mutants exposed to TCDD consis­
tently displayed a cleft palate (Figure 4D). In 
contrast, the palates of TCDD­treated Rarg–/– 
and Aldh1a3–/– mutants were invariably closed 
(Figure 4E,F). Analysis of dissected bones 
indicated that the palatal processes of maxil­
lary and palatine bones developed normally 
in Aldh1a3–/– mutants (see Supplemental 
Material, Figure 1). Most important, the 
ability of TCDD to induce cleft palate was 
restored in Aldh1a3–/– embryos rescued for 
atRA signaling through the repeated adminis­
tration of a low dose of atRA (2 mg/kg), which 
was not otherwise teratogenic for palate devel­
opment (Figure 4G–I). This demonstrates that 
atRA is the missing signal impairing the action 
of TCDD in the Aldh1a3­null genetic back­
ground. Thus, our results show that inhibi­
tion of palatal shelf development by TCDD 
Figure 2. TCDD does not modify the pattern of endogenous atRA signaling. Tg(RARE-Hspa1b/lacZ)12Jrt 
transgenic embryos were treated at GD10.5 with vehicle (A,C,E) or TCDD (B,D,F), and the outcome on atRA 
signaling was analyzed after 6 hr (A, B) and 24 hr (C–F). A–D are external views, and E and F are frontal 
histological sections of embryos after XGal staining (blue) to reveal Tg(RARE-Hspa1b/lacZ)12Jrt activity, 
which indicates atRA-responsive cells. Vehicle- and TCDD-treated fetuses show identical patterns of atRA 
activity, indicating that the dynamics and extent of atRA signaling remain unaltered upon TCDD treatment. 
Abbreviations: e, eye; ec, ectoderm; f, forebrain; lm, lateral mesenchyme of the frontonasal region; lng, 
lacrimonasal groove; mm, medial mesenchyme of the frontonasal region; mx, maxillary prominence of first 
branchial arch; ne, nasal epithelium; nr, nasal region. Bar in F = 250 μm for A and B, 360 μm for C and D, 
200 μm for E and F.
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Figure 3. TCDD does not affect atRA-dependent 
gene expression, shown by relative mRNA levels 
for atRA target genes (LacZ, Crabp2, Rara, Rarg, 
and Rxra) and a TCDD-target gene (Cyp1a1) in 
GD11.5 nasopalatal regions of Tg(RARE-Hspa1b/
lacZ)12Jrt embryos treated with vehicle or TCDD. 
Data are mean + SD of triplicates from three naso-
palatal regions in each experimental condition.
*p < 0.05.
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actually requires atRA­dependent signal(s) 
generated through the activity of RALDH3 
and mediated by RARG.
AHR expression depends on RALDH3 in 
the frontonasal region. The most straightfor­
ward explanation for the above­mentioned 
results would be that expression of AHR relies 
upon atRA synthesized by RALDH3 within 
or close to the developing palate. To test for 
this possibility, we compared expression of 
Ahr in the nasopalatal regions isolated from 
GD11.5 WT (n = 3) and Aldh1a3–/– (n = 3) 
embryos. We found a significantly decreased 
steady­state level of Ahr mRNA in mutants 
lacking RALDH3. Importantly, Ahr mRNA 
was restored to normal levels in Aldh1a3–/– 
embryos (n = 3) rescued for atRA signaling 
through the repeated administration of low, 
nonteratogenic doses of atRA (Figure 5A). 
To further assess the effect of atRA on Ahr 
expression, we examined the level of Ahr 
mRNA in WT MEFs cultured with cyclo­
heximide, an inhibitor of protein translation, 
and found a 5­fold increase upon atRA stimu­
lation (Figure 5B). This indicated that atRA­
activated RAR controlled AHR expression 
without the need for intermediate protein 
synthesis, suggesting a direct effect of RAR on 
Ahr gene. Accordingly, atRA did not increase 
Ahr mRNA levels in RAR­deficient MEFs 
(Figure 5B). Together, these results support 
the idea that Ahr expression requires atRA 
generated by RALDH3 and can explain why 
palate formation was unaffected by TCDD 
treatment in Aldh1a3–/– mutants.
Together, our findings that a) RARG, 
but not RARA, is mandatory for TCDD 
to induce cleft palate and b) RAR directly 
controls Ahr gene expression imply that the 
AHR­expressing cells at the origin of the mal­
formation are necessarily distributed within 
the domain where RARG is operational. 
Using immunohistochemistry, we found that 
RARG was expressed in the mesenchyme 
adjacent to nasal epithelium (Figure 5C,D) 
and overlapped with an active atRA signaling 
only in the mesenchyme distributed lateral to 
the nasal epithelium (compare Figures 2E and 
5C). Thus, TCDD likely acts through activat­
ing AHR present in the mesenchyme localized 
lateral to the nasal epithelium.
Discussion
Several experiments underline the impact 
of TCDD on retinoid homeostasis, but 
whether it yields states of functional vitamin 
A deficiency or excess remains a matter for 
further clarification. Overall, findings on 
TCDD­induced growth retardation, abnor­
mal immune function, and developmental 
defects reminiscent of vitamin A–deficient 
states suggest that dioxin­like compounds 
reduce atRA signaling (Murphy et al. 2007). 
Several mecha  nisms supporting this scenario 
have been proposed. First, TCDD exposure 
mobilizes retinyl esters from liver stores and 
may thus rapidly exhaust them (Nilsson and 
Håkansson 2002). Second, TCDD may 
impair RAR functioning as it inhibits both 
atRA binding and induction of target genes 
in cultured cells (Lorick et al. 1998; Weston 
et al. 1995). Third, TCDD may enhance 
atRA catabolism through inducing enzymes 
such as CYP1A1 and CYP2S1 that can 
transform atRA into less active metabolites 
(Lampen et al. 2000; Smith et al. 2003). 
An opposite set of data suggests that 
dioxin­like compounds may enhance atRA 
signaling, particularly with regard to bone 
and developmental defects (Nilsson and 
Håkansson 2002). Different scenarios have 
been proposed to explain the enhancement of 
Figure 4. TCDD is unable to induce cleft palate when atRA signaling is impaired. (A) Whole-mount in situ 
hybridization indicates restriction of Aldh1a3 expression to the nasal epithelium region. (B and C) XGal 
staining (blue) reveals Tg(RARE-Hspa1b/lacZ)12Jrt transgene activity in WT and Aldh1a3–/– embryos, illus-
trating the requirement of only RALDH3 for atRA synthesis in the nasal region. (D–I) Ventral view of palatal 
regions (Alizarin red/Alcian blue staining) of GD18.5 fetuses treated at GD10.5 with TCDD. Rara–/– mutants 
(D) displayed cleft palate, whereas Rarg–/– (E) and Aldh1a3–/– (F) mutants were resistant to this malforma-
tion. Administration of low doses of atRA (2 mg/kg every 12 hr from GD8.5 to GD12.5) failed to induce cleft 
palate in WT (G) and Aldh1a3–/– mutant (H) embryos but was sufficient to restore TCDD toxicity for palate 
development in Aldh1a3–/– mutants (I). Abbreviations: i, incisive bone; if, incisive foramen; lng, lacrimona-
sal groove; m, maxillary bone; nr, nasal region; p, palatine bone; ppi, palatal process of incisive bone; ppm, 
palatal process of maxillary bone; ppp, palatal process of palatine bone; ps, presphenoid bone; v, vomer 
bone. Bar in I = 300 μm for A–C and 1 mm for D–I.
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atRA signaling by TCDD. First, TCDD may 
increase atRA synthesis (Schmidt et al. 2003) 
because DRE have been identified in Aldh1a2 
gene coding for RALDH2, the most potent 
atRA synthesizing enzyme (Wang et al. 2001) 
and because AHR­induced CYP1A1 can par­
ticipate in atRA synthesis (Chen et al. 2000; 
Tomita et al. 1996). Second, in vitro experi­
ments indicate that TCDD induces expres­
sion of Rarg and Rrxa (Murphy et al. 2004) 
and that activated AHR is able to divert 
RARΑ from its co­repressor, thereby allowing 
the receptor to become transcriptionally active 
in the absence of atRA (Widerak et al. 2006).
Regarding development of the second­
ary palate, the present study demonstrates 
that TCDD and excess atRA share similar 
teratogenic properties when administered at 
GD10.5 as their effects are morphologically 
indistinguishable from one another, as previ­
ously reported (Abbott et al. 1989; Moore 
et al. 1973). Furthermore, a combination of 
low doses of each compound synergistically 
induces this defect (Birnbaum et al. 1989). 
Thus, an interaction exists between dioxin­
  induced and atRA­dependent events involved 
in this developmental defect. The possibil­
ity that a decrease in atRA signaling could 
account for TCDD­induced effects appears 
unlikely because the palatal malformations 
generated upon functional vitamin A defi­
ciency or Rar gene ablations a) affect essen­
tially the development of the primary palate 
and b) are never isolated, but instead occur 
as part of a holoprosencephaly syndrome 
(Lohnes et al. 1994). These features are clearly 
distinct from those of dioxin­induced cleft 
palates. We therefore explored the possibility 
that TCDD exposure during gestation may 
enhance atRA signaling through increasing 
either atRA levels or RAR activity. Our exper­
iments using mice harboring an atRA­sensitive 
reporter transgene, as well as the quantitative 
analysis of atRA­target gene expression in the 
palatal region, revealed that TCDD does not 
modify the pattern of atRA signaling in the 
facial region during palate development.
In contrast, because Aldh1a3–/– and 
Rarg–/– mutants are resistant to TCDD­
induced clefts, our study provides evidence 
that a functional, intact atRA signal origi­
nating from RALDH3, which is the sole 
atRA­synthesizing enzyme expressed in the 
palatal region and mediated by RARG in the 
facial mesenchyme, is required for TCDD 
to exert teratogenic effects on palate devel­
opment. Accordingly, we provide evidence 
that the atRA signaling pathway is instrumen­
tal in AHR signaling in the palatal region, 
notably through controlling Ahr transcript 
levels [see Supplemental Material, Figure 3 
(http://dx.doi.org/10.1289/ehp.1003075)]. 
Even though no atRA­response element is 
characterized in this gene, we show a direct 
involvement of atRA­activated RAR in this 
process. Interestingly, a role of atRA and 
RAR in the control of AHR expression has 
been previously demonstrated in medaka fish 
(Hayashida et al. 2004). Because RARs exert 
their functions heterodimerized with RXRA 
during mouse development (Mark et al. 
2006), it is likely that RARG acts with RXRA 
to control AHR expression. This hypothe­
sis, however, cannot be confirmed because 
Rxra–/– mutants die before the completion of 
palate closure (reviewed in Mark et al. 2006). 
Nonetheless, our finding that Rxra expression 
was unchanged after TCDD exposure and 
the fact that RXRA is not activated by atRA 
(Duester 2008) together support the view 
that RXRA plays no major role aside from its 
partnership with RARG. Importantly, the fact 
that Ahr–/– mice developed cleft palates upon 
atRA excess allows us to rule out the possibil­
ity that atRA binds to and activates AHR, as 
opposed to other retinoids (Gambone et al. 
2002; Soprano and Soprano 2003; Soprano 
et al. 2001). We also excluded the possibil­
ity that TCDD acts through binding to, 
and activating, RARG because ablation of 
Aldh1a3 was sufficient to prevent TCDD­
induced cleft palate.
AHR expression has been detected in the 
developing mouse at several sites and distinct 
time points (Abbott et al. 1995). In addi­
tion, the temporal and spatial context of AHR 
activation after TCDD exposure in vivo has 
been determined in a transgenic mouse model 
(Willey et al. 1998). Together, these studies, 
which focused mainly on elevation and fusion 
of palatal shelves, have highlighted roles of AHR 
in mesenchyme and epithelium at GD14.5 
but did not identify the cell type(s) that were 
targeted by TCDD at GD10.5. Interestingly, 
our study indicates that AHR is required at 
GD10.5 in the mesenchyme lateral to the nasal 
epithelium. Therefore, at the beginning of 
palato  genesis, TCDD does not act directly on 
nascent, first­arch–derived palatal shelves, but 
rather on the frontonasal mesenchyme distrib­
uted lateral to the nasal epithelium.
Conclusions
Our results indicate that atRA­activated 
RARG controls the expression of AHR at 
GD10.5 in the developing palate, which in 
turn appears necessary for TCDD to induce 
cleft palate. TCDD, however, does not alter 
the pattern of atRA­signaling in the devel­
oping face. These findings provide evidence 
about the molecular mechanism through 
which TCDD exposure at GD10.5 can result 
in a cleft palate and thereby clarify a possible 
mechanism of action for TCDD. The eti­
ology of cleft palate induced by TCDD at 
later developmental stages (e.g., GD12.5) 
may stem from another mechanism (Abbott 
and Birnbaum 1990; Birnbaum et al. 1989). 
Nonetheless, because both AHR and RAR are 
universal signaling systems conserved across 
vertebrate species, including humans (Campo­
Paysaa et al. 2008; Hahn 2002), it is possible 
that the mechanistic findings in the present 
study are of general relevance. Accordingly, 
Figure 5. AHR expression depends upon RALDH3 in the frontonasal region. (A and B) Relative Ahr mRNA 
levels in GD11.5 nasopalatal regions of WT, Aldh1a3–/– and atRA-rescued (2 mg/kg) Aldh1a3–/– embryos (A) 
and in WT or RAR-deficient MEFs treated with vehicle or atRA (B). Data are the mean + SD of triplicates 
from at least three samples (nasopalatal regions or cell cultures) in each experimental condition. (C and 
D) Immunohistochemistry showing RARG protein localization in the mesenchyme surrounding the nasal 
epithelium in WT embryo (C). An Rarg–/– embryo was used as a negative control for immunostaining (D). 
Abbreviations: f, forebrain; lm, lateral mesenchyme of the frontonasal region; lng, lacrimonasal groove; 
mm, medial mesenchyme of the frontonasal region; mx, maxillary prominence of first branchial arch; ne, 
nasal epithelium. Bar = 200 μm.
*p < 0.05 in ligand-treated versus vehicle-treated samples.
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Ahr expression is controlled by atRA­activated 
RAR both in mouse (present study) and in 
medaka fish (Hayashida et al. 2004). In this 
context, intact atRA signaling may be manda­
tory to enable the AHR message not only in 
the developing palate at GD10.5 but also in 
other organ systems.
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